Acute myeloid leukemia in the elderly: therapeutic options and choice

Jonathan A. Webster, Keith W. Pratz

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Acute myeloid leukemia (AML) therapies are rapidly evolving with novel targeted therapies showing high-level responses in a notoriously difficult to treat group of patients–the elderly and unfit. This review will examine the outcomes of older AML patients (>60 years old) with conventional induction strategies, and published literature on risks of pursuit of induction. Low-intensity combination therapy response rates appear to be approaching that of induction regimens, and with lower toxicity, low-intensity therapy likely represents the future standard approach in this age group. Lastly, allogeneic transplant appears to have a role in increasing durable remissions regardless of age and should be considered in patients with limited comorbidities.

Original languageEnglish (US)
Pages (from-to)274-287
Number of pages14
JournalLeukemia and Lymphoma
Issue number2
StatePublished - Feb 1 2018


  • AML
  • elderly
  • therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Acute myeloid leukemia in the elderly: therapeutic options and choice'. Together they form a unique fingerprint.

Cite this